JP2022551185A5 - - Google Patents
Info
- Publication number
- JP2022551185A5 JP2022551185A5 JP2022521718A JP2022521718A JP2022551185A5 JP 2022551185 A5 JP2022551185 A5 JP 2022551185A5 JP 2022521718 A JP2022521718 A JP 2022521718A JP 2022521718 A JP2022521718 A JP 2022521718A JP 2022551185 A5 JP2022551185 A5 JP 2022551185A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered heterocycloalkyl
- branched
- pharmaceutically acceptable
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH01281/19 | 2019-10-09 | ||
| CH12812019 | 2019-10-09 | ||
| PCT/EP2020/078483 WO2021069705A1 (en) | 2019-10-09 | 2020-10-09 | Isoindolinone compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551185A JP2022551185A (ja) | 2022-12-07 |
| JP2022551185A5 true JP2022551185A5 (enExample) | 2023-10-17 |
| JP7724394B2 JP7724394B2 (ja) | 2025-08-18 |
Family
ID=68242216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521718A Active JP7724394B2 (ja) | 2019-10-09 | 2020-10-09 | イソインドリノン化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220242846A1 (enExample) |
| EP (1) | EP4041231A1 (enExample) |
| JP (1) | JP7724394B2 (enExample) |
| WO (1) | WO2021069705A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7871189B2 (ja) * | 2019-12-17 | 2026-06-08 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| CN122562781A (zh) * | 2020-10-07 | 2026-08-14 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| CN117242060B (zh) * | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| WO2022152822A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Treatment of myc-driven cancers with gspt1 degraders |
| WO2022153220A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Methods for the identification of degrons |
| EP4313047A1 (en) * | 2021-03-22 | 2024-02-07 | Monte Rosa Therapeutics, Inc. | Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons |
| US20240287573A1 (en) | 2021-06-04 | 2024-08-29 | Monte Rosa Therapeutics, Inc. | E3 ligase fusion proteins for proximity detection |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023001028A1 (zh) * | 2021-07-19 | 2023-01-26 | 南京明德新药研发有限公司 | 杂芳-3-哌啶二酮类化合物及其应用 |
| WO2023069720A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023069708A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and uses thereof |
| WO2023069700A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023091567A1 (en) | 2021-11-17 | 2023-05-25 | Monte Rosa Therapeutics, Inc. | Degron and neosubstrate identification |
| EP4508044A1 (en) | 2022-04-14 | 2025-02-19 | Bristol-Myers Squibb Company | Novel gspt1 compounds and methods of use of the novel compounds |
| EP4554581A1 (en) | 2022-07-13 | 2025-05-21 | Monte Rosa Therapeutics AG | Combination therapy comprising gspt1-directed molecular glue degraders and pi3k/akt/mtor pathway inhibitors |
| CN119630648A (zh) * | 2022-07-14 | 2025-03-14 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮衍生物的制备方法及其晶形 |
| WO2024027795A1 (zh) * | 2022-08-04 | 2024-02-08 | 苏州开拓药业股份有限公司 | 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| KR20260005248A (ko) * | 2023-03-24 | 2026-01-09 | 주식회사 핀테라퓨틱스 | Gspt1 분해 화합물 및 분해 방법 |
| WO2025051180A1 (zh) * | 2023-09-06 | 2025-03-13 | 上海超阳药业有限公司 | 内酰胺类衍生物及其应用 |
| KR20260094777A (ko) * | 2023-10-16 | 2026-06-23 | 브리스톨-마이어스 스큅 컴퍼니 | Gspt1 화합물 및 상기 화합물의 사용 방법 |
| WO2025146112A1 (en) * | 2024-01-05 | 2025-07-10 | Primelink Biotherapeutics (Shenzhen) Co., Ltd. | Gspt1 degrading compounds and compositions and uses thereof |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
| WO2025259615A1 (en) * | 2024-06-11 | 2025-12-18 | Triana Biomedicines, Inc. | Modulators of cdk2 and uses thereof |
| WO2026007898A1 (zh) * | 2024-07-01 | 2026-01-08 | 上海海雁医药科技有限公司 | 含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用 |
| WO2026060296A2 (en) * | 2024-09-13 | 2026-03-19 | Uab Research Foundation | Compounds for the treatment of cystic fibrosis |
| WO2026154063A1 (en) | 2025-01-16 | 2026-07-23 | Monte Rosa Therapeutics Ag | Reverse turboid |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| AU2007290407A1 (en) | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
| CA2957226C (en) | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| AR108222A1 (es) | 2016-05-05 | 2018-08-01 | Elanco Tiergesundheit Ag | Compuestos heteroaril-1,2,4-triazol y heteroaril-tetrazol |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| JP2021512153A (ja) * | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| US20230338564A1 (en) * | 2020-03-31 | 2023-10-26 | Orum Therapeutics, Inc. | Neodegrader conjugates |
-
2020
- 2020-10-09 JP JP2022521718A patent/JP7724394B2/ja active Active
- 2020-10-09 WO PCT/EP2020/078483 patent/WO2021069705A1/en not_active Ceased
- 2020-10-09 EP EP20789952.7A patent/EP4041231A1/en active Pending
-
2022
- 2022-04-08 US US17/716,169 patent/US20220242846A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024504932A5 (enExample) | ||
| JP2022510313A5 (enExample) | ||
| JP2023553835A5 (enExample) | ||
| JP2012505871A5 (enExample) | ||
| JP2022539089A5 (enExample) | ||
| JP2020169171A5 (enExample) | ||
| JP2021514001A5 (enExample) | ||
| JP2010506854A5 (enExample) | ||
| JP2007501859A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2013542223A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| JP2009536660A5 (enExample) | ||
| JP2011520815A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2010138190A5 (enExample) | ||
| RU2011127079A (ru) | Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с | |
| JP2014527974A5 (enExample) | ||
| RU2017121906A (ru) | Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии | |
| JP2022522694A5 (enExample) | ||
| JP2010514786A5 (enExample) | ||
| RU2010133903A (ru) | Способ и промежуточные соединения для получения производных 5-бифенил-4-ил-2-метилпентановой кислоты | |
| JP2016518434A5 (enExample) | ||
| JP2024541910A5 (enExample) | ||
| JP2008505157A5 (enExample) |